Trimel Pharmaceutica (TRLPF) 0.3700 $TRLPF
CORRECTION FROM SOURCE: Trimel Reports Third Quarter 2014 Financial Results
Marketwire Canada - Thu Nov 06, 10:37AM CST
Trimel Pharmaceuticals Corporation (TSX:TRL) -
TRL.TO: 0.45 (unch)
Trimel Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 7:09AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today reported financial results for the three month period ended September 30, 2014 and highlighted important corporate activities. Unless otherwise noted, all dollars amounts shown in this press release are in U.S. dollars.
TRL.TO: 0.45 (unch)
Trimel to Report Third Quarter 2014 Results and Host Conference Call to Update Investors
Marketwired - Wed Oct 29, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its third quarter financial results for the period ended September 30, 2014 on Thursday, November 6, 2014 before markets open.
TRL.TO: 0.45 (unch)
First Generation Capital Inc. Converts a Portion of Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Fri Aug 22, 5:28PM CDT
Mr. Ian Ihnatowycz announced that effective today, he has converted US$5,151,768.08 aggregate amount (of which US$55,002.59 was accrued interest) of obligations owing under the convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" that was issued to First Generation Capital Inc. on July 16, 2014 (and amended on July 28, 2014) into 8,945,796 common shares of the Issuer. In accordance with the terms and conditions of the Note, the conversion price was the U.S. dollar equivalent of Cdn.$0.62 per common share, calculated using the Bank of Canada noon rate of exchange on July 15, 2014 (being a conversion price equal to US$0.5759 per common share).
Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
TRL.TO: 0.45 (unch)
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
SHPG: 202.62 (+0.20), TRL.TO: 0.45 (unch)
First Generation Capital Inc. Amends Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Wed Jul 30, 1:56PM CDT
Mr. Ian Ihnatowycz, announced that effective today, he has entered into an amending agreement (the "Amending Agreement" to the US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" issued on July 16, 2014 to his private investment holding company First Generation Capital Inc. (the "Offeror".
Trimel to Provide Corporate Update and Report Second Quarter 2014 Results
Marketwire - Fri Jul 18, 7:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2014 on July 30, 2014 after market close.
TRL.TO: 0.45 (unch)
First Generation Capital Inc. Acquires Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Thu Jul 17, 1:20PM CDT
Mr. Ian Ihnatowycz announced today that he has acquired a US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" through his private investment holding company First Generation Capital Inc. (the "Offeror". The Note, which pays interest at 9.5% plus the greater of: (a) LIBOR; and (b) 1.0%, and has an initial maturity date of July 16, 2015, is convertible into common shares of the Issuer, in whole or in part at any time after August 21, 2014, at a conversion price, subject to standard anti-dilution adjustments, of the US dollar equivalent of $0.62 (calculated using the July 15, 2014 Bank of Canada noon buying rate for US dollars of US$1 equals $1.0766). The purchase was made on a private placement basis from the Issuer.
IIROC Trade Resumption - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:51PM CDT
Trading resumes in:
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:50PM CDT
The following issues have been halted by IIROC:
CORRECTION FROM SOURCE: Trimel Reports Third Quarter 2014 Financial Results
Marketwire Canada - Thu Nov 06, 10:37AM CST
Trimel Pharmaceuticals Corporation (TSX:TRL) -
TRL.TO: 0.45 (unch)
Trimel Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 7:09AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today reported financial results for the three month period ended September 30, 2014 and highlighted important corporate activities. Unless otherwise noted, all dollars amounts shown in this press release are in U.S. dollars.
TRL.TO: 0.45 (unch)
Trimel to Report Third Quarter 2014 Results and Host Conference Call to Update Investors
Marketwired - Wed Oct 29, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its third quarter financial results for the period ended September 30, 2014 on Thursday, November 6, 2014 before markets open.
TRL.TO: 0.45 (unch)
First Generation Capital Inc. Converts a Portion of Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Fri Aug 22, 5:28PM CDT
Mr. Ian Ihnatowycz announced that effective today, he has converted US$5,151,768.08 aggregate amount (of which US$55,002.59 was accrued interest) of obligations owing under the convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" that was issued to First Generation Capital Inc. on July 16, 2014 (and amended on July 28, 2014) into 8,945,796 common shares of the Issuer. In accordance with the terms and conditions of the Note, the conversion price was the U.S. dollar equivalent of Cdn.$0.62 per common share, calculated using the Bank of Canada noon rate of exchange on July 15, 2014 (being a conversion price equal to US$0.5759 per common share). Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
TRL.TO: 0.45 (unch)
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
SHPG: 202.62 (+0.20), TRL.TO: 0.45 (unch)
First Generation Capital Inc. Amends Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Wed Jul 30, 1:56PM CDT
Mr. Ian Ihnatowycz, announced that effective today, he has entered into an amending agreement (the "Amending Agreement"
to the US$25 million convertible note (the "Note" of Trimel Pharmaceuticals Corporation (the "Issuer" issued on July 16, 2014 to his private investment holding company First Generation Capital Inc. (the "Offeror". Trimel to Provide Corporate Update and Report Second Quarter 2014 Results
Marketwire - Fri Jul 18, 7:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2014 on July 30, 2014 after market close.
TRL.TO: 0.45 (unch)
First Generation Capital Inc. Acquires Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Thu Jul 17, 1:20PM CDT
Mr. Ian Ihnatowycz announced today that he has acquired a US$25 million convertible note (the "Note"
of Trimel Pharmaceuticals Corporation (the "Issuer" through his private investment holding company First Generation Capital Inc. (the "Offeror". The Note, which pays interest at 9.5% plus the greater of: (a) LIBOR; and (b) 1.0%, and has an initial maturity date of July 16, 2015, is convertible into common shares of the Issuer, in whole or in part at any time after August 21, 2014, at a conversion price, subject to standard anti-dilution adjustments, of the US dollar equivalent of $0.62 (calculated using the July 15, 2014 Bank of Canada noon buying rate for US dollars of US$1 equals $1.0766). The purchase was made on a private placement basis from the Issuer. IIROC Trade Resumption - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:51PM CDT
Trading resumes in:
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Thu Jul 17, 12:50PM CDT
The following issues have been halted by IIROC:
